Literature DB >> 1665897

Neuropeptide gamma, the most potent contractile tachykinin in human isolated bronchus, acts via a 'non-classical' NK2 receptor.

E Burcher1, L A Alouan, P R Johnson, J L Black.   

Abstract

Cumulative contractile response curves to neurokinin A (NKA) and neuropeptide gamma (NP gamma) were obtained in human isolated bronchus, in the presence of phosphoramidon 10 microM. NP gamma was approximately 10-fold more potent than NKA (pD2 values 8.6 +/- 0.4 and 7.3 +/- 0.3 respectively, n = 6; P less than 0.01). The NK1-selective agonist [Sar9, Met(O2)11]-SP and the NK3 selective agonist senktide produced negligible contraction. Response curves to NP gamma and NKA were unaffected by the NK2 subtype-selective antagonist MDL 29913 at 2 microM, but NP gamma-induced contraction was markedly inhibited by 20 microM MDL 29,913. Thus NP gamma is the most potent tachykinin in human isolated bronchus and its effects are mediated at a receptor which is not of the 'classical' NK2 subtype found in hamster urinary bladder.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665897     DOI: 10.1016/0143-4179(91)90055-n

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  3 in total

1.  Characterization of the [125I]-neurokinin A binding site in the circular muscle of human colon.

Authors:  F J Warner; A Comis; R C Miller; E Burcher
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Intracerebroventricular responses to neuropeptide gamma in the conscious rat: characterization of its receptor with selective antagonists.

Authors:  P Picard; R Couture
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

3.  Tachykinin receptors in rabbit airways--characterization by functional, autoradiographic and binding studies.

Authors:  J L Black; L M Diment; L A Alouan; P R Johnson; C L Armour; T Badgery-Parker; E Burcher
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.